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Cerebrotendinous xanthomatosis (CTX) OMIM#213700 is a rare autosomal-recessive lipid storage disease caused by
mutations in the CYP27A1 gene; this gene codes for the mitochondrial enzyme sterol 27-hydroxylase, which is
involved in bile acid synthesis. The CYP27A1 gene is located on chromosome 2q33-qter and contains nine exons.
A CYP27A1 mutation leads to decreased synthesis of bile acid, excess production of cholestanol, and consequent
accumulation of cholestanol in tissues. Currently there is no consensus on the prevalence of CTX, one estimate
being <5/100,000 worldwide. The prevalence of CTX due to the CYP27A1 mutation R362C alone is approximately
1/50,000 in Caucasians. Patients with CTX have an average age of 35 years at the time of diagnosis and a diagnostic
delay of 16 years. Clinical signs and symptoms include adult-onset progressive neurological dysfunction (i.e., ataxia,
dystonia, dementia, epilepsy, psychiatric disorders,peripheral neuropathy, and myopathy) and premature non-neurologic
manifestations (i.e., tendon xanthomas, childhood-onset cataracts, infantile-onset diarrhea, premature atherosclerosis,
osteoporosis, and respiratory insufficiency). Juvenile cataracts, progressive neurologic dysfunction, and mild pulmonary
insufficiency are unique symptoms that distinguish CTX from other lipid storage disorders including familial
dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and sitosterolemia, all of which might also
present with xanthomas and cardiovascular diseases. Brain magnetic resonance imaging (MRI) shows bilateral
lesions in the dentate nucleus of the cerebellum and mild white matter lesions. The classical symptoms and signs,
namely elevated levels of cholestanol and bile alcohols in serum and urine, brain MRI, and the mutation in the
CYP27A1 gene confirm the diagnosis of CTX. Early diagnosis and long-term treatment with chenodeoxycholic acid
(750 mg/d) improve neurological symptoms and contribute to a better prognosis.
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Cholic acidIntroduction
Definition, history, epidemiology
Cerebrotendinous xanthomatosis (CTX; OMIM#213700)
is a rare autosomal-recessive inborn disorder of bile acid
metabolism due to mutations in the CYP27A1 gene
(OMIM *606530) located on chromosome 2q33-qter, lead-
ing to increased deposition of cholesterol and cholestanol
in multiple tissues [1]. Since Bogaert’s first report in 1937
of a case of CTX, more than several hundred cases have* Correspondence: zhangyunjian66@126.com
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unless otherwise stated.been reported worldwide [2,3]. CTX may have a higher
prevalence than usually recognized. There are no consen-
sus data on the prevalence of CTX, the estimated rate be-
ing <5/100,000 worldwide [4]. The prevalence of this
disease varies with country and ethnic group; the preva-
lence of CTX due to the CYP27A1 mutation R362C alone
is 1/800,000 individuals in Spain and is approximately
1/50,000 in Caucasians [4,5].Etiology and biochemical pathogenesis
In 1974, Setoguchi et al. first found that the decrease in
bile acid synthesis in patients with CTX resulted from
impaired oxidation of the cholesterol side-chain, which
suggested that CTX is linked to a disorder of bile acid. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Nie et al. Orphanet Journal of Rare Diseases 2014, 9:179 Page 2 of 11
http://www.ojrd.com/content/9/1/179synthesis [6]. Patients with CTX lack mitochondrial
sterol 27-hydroxylase (EC 1.14.13.15). This enzyme is lo-
cated on the inner membranes of the mitochondria, is
expressed in almost all cells of the body, and is an
important enzyme in both the alternative and classic
bile acid synthesis pathways [7,8]. Cholesterol 7α-
hydroxylase (CYP7A1) is the rate-limiting enzyme in
the classic pathway. In the alternative pathway, sterol
27-hydroxylase (CYP27A1) oxidizes cholesterol to 27-
hydroxycholesterol, which is subsequently hydroxylated
by oxysterol 7α-hydroxylase, leading in humans mostly
to the formation of chenodeoxycholic acid (CDCA)
[8-10]. A deficiency of sterol 27-hydroxylase leads to re-
duced production of CDCA and subsequently to upregu-
lation of cholesterol 7α-hydroxylase. Upregulation of the
rate-limiting enzyme in the classic bile acid pathway re-
sults in elevated levels of 7α-hydroxy-4-cholesten-3-one,
an efficient precursor to cholestanol [3]. Most of the
cholestanol accumulated in patients with CTX is derived
from 7α-hydroxylated metabolites of cholesterol, 7α-
hydroxy-4-cholesten-3-one being the most important
[3,11]. Development and progression of CTX are sec-
ondary to the further efficient conversion of 7α-hydroxy-
4-cholesten-3-one into cholestanol and bile alcohols by
two different pathways [3,12] (Figure 1).
General symptoms
Patients with CTX present diverse manifestations with
multi-organ involvement and a broad range of neuro-
logical and non-neurological symptoms [13]. For example,
intractable infantile-onset diarrhea and psychomotor re-
tardation are common coexisting clinical features of CTX
[14,15]. The mean age at onset of symptoms in patientsFigure 1 Metabolic pathway involved in cerebrotendinous xanthoma
mutation in the CYP27A1 gene, cholesterol cannot be converted into bile a
Providing chenodeoxycholic acid exogenously has a negative feedback eff
of cholestanol.with CTX is 19 years, but the average age at the time of
diagnosis is 35 years (range 23–44), thus representing a
diagnostic delay of 16 years (range 2–34) [5].
Central nervous system involvement
Central nervous system symptoms and signs commonly
present and sometimes constitute the initial manifesta-
tions in patients with CTX [16-22]. Epilepsy and Parkin-
sonism are the initial neurological features of CTX
[19,20]. In a retrospective study involving 25 patients in
Spain, Pilo-de-la-Fuente et al. divided the neurological
manifestations into two main clinical subgroups, the
classic form (cerebellar and supratentorial symptoms)
and the spinal form (chronic myelopathy) [5]. The range
of neurological features of CTX reported in the litera-
ture is broad; these features include intellectual disabil-
ity, dementia, psychiatric symptoms (i.e., behavioral
changes, depression, agitation, hallucination, and suicide
attempts), pyramidal signs, progressive ataxia, dystonia,
and palatal myoclonus [16,17,19-21,23-26].
Ocular system involvement
Childhood-onset cataract is a typical sign of CTX [13-15].
This has been emphasized as an early symptom preceding
neurological signs and tendon xanthoma, and is considered
useful for early diagnosis. Cataracts and optic disk paleness
are also the common ocular features in adults with CTX
[21]. Other ocular abnormalities in CTX include retinal
vessel sclerosis and cholesterol-like deposits [21,27].
Cardiovascular system involvement
Premature atherosclerosis and cardiovascular disease have
been reported among the multiple clinical manifestationstosis (CTX; modified from Chales and Bjorkhem [10,74]). Due to a
cids, but is instead converted into cholestanol and bile alcohol.
ect that reduces synthesis of bile acid, thus preventing accumulation
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mature atherosclerosis in spite of normal serum choles-
terol concentrations [29]. Blood lipid analysis in patients
with CTX revealed dramatically high levels of 27-
hydroxycholesterol and low levels of high-density lipopro-
tein cholesterol,which place patients with CTX at a high
risk of suffering from cardiovascular disease [30].
Skeletal system involvement
Osteoporosis and repeated bone fractures are also com-
mon clinical manifestations of patients with CTX. Low
bone mass in the patient with severe gait disturbances
increases the risk of accidental falls and bone fractures
[31-33]. Federico et al. discovered that serum calcium,
phosphate, and vitamin D metabolites in CTX patients
were normal, but the total body bone mineral density
was low and intestinal radiocalcium absorption was de-
creased [33]. However, the underlying pathogenesis is
still unknown. There is no correlation between the se-
verity of osteoporosis and biochemical parameters
(i.e. cholestanol level, phenotypic data, and disability
associated with neurological dysfunction) in patients
with CTX [32].
Pulmonary system involvement
Kawabata et al. discovered accumulations of foamy and
giant cells engorged with cholestanol in bronchoalveolar
lavage fluids and lung biopsy of patients with CTX, which
demonstrated that the lungs are involved in CTX [34]. Pa-
tients with CTX with pulmonary involvement may have
no clinical pulmonary symptoms (e.g., shortness of breath,
chest distress) and no disturbance in pulmonary function
tests [34]. Based on the results of positron emission tom-
ography (PET), we found a high-density lesion (12 ×
14 mm) and a cyst with a gas-fluid level (16 × 20 mm) in
the lung of a patient with CTX (Figure 2). Pulmonary lym-
phangioleiomyomatosis was detected in a patient with
CTX, but whether there is an association between these
two rare diseases is unknown [35].
Enterohepatic system involvement
In a large series of 32 patients with CTX studied by the
Verrips et al., 50% had chronic and intractable diarrhea,
which began in childhood [36]. Ninety-two percent of the
patients with CTX in another large retrospective study in
Spain had chronic diarrhea [5]. However, the gastro-
intestinal examinations in many of the patients with diar-
rhea were normal [37]. Diarrhea in patients with CTX
disappears a shortly after the start of CDCA therapy; how-
ever, the underlying mechanism is unknown [15,36,37].
This may be partly because bile alcohols produced in CTX
are replaced by CDCA, which is an excellent micelle-
forming bile acid, thereby improving fat and fat-soluble
vitamin absorption and the attendant diarrhea. Some patientswith CTX also develop neonatal cholestatic jaundice, cho-
lecystic polypus, and gallstones [21,38].
Peripheral nervous system and muscle involvement
Ginanneschi et al. revealed that 74.2% of patients with
CTX (n =35) showed peripheral nerve abnormalities [39].
Demyelination and remyelination, features of axonal de-
generation, can be found in patients with CTX [40]. Mild
myopathic changes and ultrastructural abnormalities in
mitochondria are observed in muscle lesions [41]. Of note,
the presence of tendon xanthomas is not necessary for the
diagnosis of CTX because not all patients have visible ten-
don xanthomas.
Laboratory findings
The biochemical abnormalities in CTX include a plasma
cholestanol concentration five- to ten-fold greater than
normal (330 ± 30 μg/dL), a urine bile alcohol concentra-
tion of 14,000 ± 3,500 nmol/L, and a plasma bile alcohol
concentration more than 500- to 1,000-fold greater than
normal (8.48 ± 3.67 nmol/L). The biochemical abnormal-
ities that distinguish CTX from other diseases with xan-
thomas include: high plasma cholestanol concentration,
normal-to-low plasma cholesterol concentration, de-
creased CDCA level, and increased levels of cholestanol
and apolipoprotein B in cerebrospinal fluid [42]. An ele-
vated plasma 5-α-cholestanol concentration detected by
gas chromatography–mass spectrometry (GC-MS) is a
biomarker for CTX [43].
Instrumental examinations
Transcranial magnetic stimulation (TMS) is a useful tool
for detecting corticospinal tract damage and for evaluating
improvements in pyramidal function after CDCA therapy
[44]. In CTX, abnormalities are seen in neurophysiological
examinations such as visual evoked potential (VEP), som-
atosensory evoked potential (SSEP), brainstem auditory
evoked potential (BAEP), and nerve conduction velocity
(NCV), tests that have been widely described [5,39,45-47].
Imaging
Imaging studies have a significant role to play in prompt
diagnosis.
First, the brain MRI reveals cerebellar atrophy, white
matter signal alterations, and symmetric hyperintensities in
the dentate nuclei [42,48-53] (Figure 3). Gray matter (GM)
and white matter (WM) volume are diffusely decreased in
patients with CTX [54,55]. In additional to conventional
MRI, diffusion tensor imaging (DTI) and voxel-based
morphometry (VBM) can provide complementary informa-
tion about the involvement of GM and WM in CTX [54].
DTI is a useful tool for detecting white matter tract
changes, because it is sensitive to water diffusion. VBM as
an unbiased brain quantitative method that can be used to
Figure 2 Positron emission tomography (PET) imaging results in CTX: pulmonary system involvement. PET reveals a cyst with a gas-fluid
level (16 × 20 mm, A and B) and a high-density lesion (12 × 14 mm, C) in the lung.
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vious magnetic resonance spectroscopy (MRS) studies
revealed increased lactate and lipid peaks in FLAIR-
hypointense lesions and decreases in N-acetylaspartate
(NAA) peaks diffusely [49,51,57,58]. SPECT imaging re-
veals regional cerebral blood flow (rCBF) changes in mul-
tiple brain lobes before and after therapy, which might be
a useful tool for monitoring the response to therapy in
patients with CTX [54,59,60]. SPECT imaging can assess
mitochondrial status and presynaptic dopaminergic function
(using the special photographic developers 99mTc-sestamibi
and 123I-FP-CIT, respectively) associated with Parkinson-
ian symptoms in CTX [61,62]. Using 18F-6-fluoro-L-dopa
for PET analysis, Kuwabara et al. found reduced uptake
of dopamine into the putamen in a patient with bothFigure 3 MRI results: brain. Brain MRI shows T1-weighted (A, arrow) andCTX and hemiparkinsonism, suggesting a dysfunction of
presynaptic dopaminergic neurons, which is not classical
in CTX [63]. The PET images exhibited remarkable differ-
ences in basal brain metabolic rate between patients with
CTX and normal volunteers (Figure 4).
Second, MRI of both ankles shows fusiform thickening
and heterogeneous signals [24] (Figure 5). Moreover, PET
analysis using 18F-2-deoxy-2-fluoro-glucose shows abnor-
mally high radioactivity in the Achilles tendons and adjacent
regions (Standardized Uptake Value 8.7-13.6) (Figure 6).
Third, radiological images of the lung have been re-
ported in several cases with CTX. The lesions in the
lungs manifest as diffuse, nodular, infiltrated, and fibrotic
shadows, which suggests interstitial pulmonary dysfunc-
tion or xanthomatous lesions [21,34,35].T2-weighted (B, arrow) hyperintensities in the dentate nuclei.
Figure 4 PET imaging results: brain. Remarkable abnormalities are seen in the basal brain metabolic rate in a patient with CTX. PET reveals
hypometabolism in cerebral lobes (especially in the frontal and temporal lobes) in sagittal section (A), and in axial section (B).
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Macroscopic section of the brain shows brain atrophy with
multiple yellowish deposits in the plexus choroideus and
in brain white matter [64]. Under microscopic examin-
ation, pathological findings in the central nervous system
in CTX include multiple dispersed lipid crystal clefts and
granulomatous lesions in the cerebellar hemispheres, de-
myelination and perivascular accumulation of foamy
macrophages in the globus pallidus, and extracellular de-
position of homogeneous myelin-like material in periven-
tricular areas [52,64-66]. Demyelination, gliosis, and
involvement of the long tracts of the spinal cord have also
been described [52,67]. Nerve biopsy reveals primary
axonal degeneration, demyelination, and remyelination
[40,68-70]. The pathological findings from needle aspir-
ation and autopsy of the lungs of patients with CTX
reveal granulomatous materials, foamy cells, and intracel-
lular accumulations of foreign bodies [34,35,71]. Histo-
pathology of the tendon masses shows an accumulation ofFigure 5 5 MRI results: tendon. MRI of both ankles. Sagittal long-T1-weig
axial long-T1-weighted image (C, arrow) of fusiform thickenings in the Achxanthoma cells and multiple, dispersed lipid crystal clefts
[70] (Figure 7). Under electron microscopic examination,
ultrastructural abnormalities are found in the lesions, in-
cluding subsarcolemmal accumulation in mitochondria
and swollen sarcoplasmic reticulum [46].
Genetic analysis
The gene coding for sterol 27-hydroxylase was first lo-
cated on the q33-qter interval of human chromosome 2
and mouse chromosome 1 by the group of Russell [1].
DNA sequence analysis of CYP27A1 predicted a human
sterol 27-hydroxylase consisting of a 33 amino-acid
mitochondrial signal sequence followed by 498 amino
acids [1]. Various mutations in all nine exons and in in-
trons 2,4,6,7, and 8 of the CYP27A1 gene have been
described worldwide [8]. Fifty percent of mutations
in CYP27A1 have been detected in the region of exons
6–8, 16% in exon 2, and 14% in exon 4 [8,72]. Various
mutation types, including missense (approximately 45%),hted image (A, arrow) and short-T2-weighted image (B, arrow), and
illes tendons in a patient with CTX.
Figure 6 PET imaging results: tendon. Unusually high radioactivity is found in both Achilles tendons of a patient with CTX. PET shows
abnormal soft-tissue thickening in a CT window in coronal section (A) and in axial section (D), and unusually high radioactivity in Achilles tendons
and adjacent regions in PET (B and E) and fusion windows (C and F).
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(14%), and insertion (2%) have been detected in all nine
exons of CYP27A1 [2]. No genotype-phenotype correla-
tions have been identified in CTX [2,5,73]. It is notable
that CYP27A1 was identified as a candidate gene for
sporadic amyotrophic lateral sclerosis in a large genome-
wide screening study [74,75].
Differential diagnosis
Sitosterolemia
Sitosterolemia (OMIM#210250), is a very rare inherited
sterol storage disease caused by mutations in the adeno-
sine triphosphate-binding cassette (ABC) transporter
genes ABCG5 and ABCG8, which are located on chromo-
some 2p21 and expressed at the membrane of entero-
hepatic cells [76-78]. Around 100 sitosterolemia cases
have been reported in the literature [79]. Increased ab-
sorption and decreased excretion of plant sterols are theFigure 7 Histology: tendon. HE staining of the tendon masses reveals ac
clefts (coarse arrows). A, 100×; B, 200 × .metabolic characteristics of sitosterolemia [22,80]. Clinical
manifestations are characterized by extensive tuberous
and tendonous xanthomas, premature atherosclerosis,
hemolytic anemia, arthritis, and thrombocytopenic pur-
pura [79,81,82]. Laboratory findings included high plasma
phytosterol concentration and normal to mildly elevated
plasma cholesterol concentrations [22,79]. Combined
treatment with ezetimibe and a low plant-sterol diet can
be effective in reducing plant sterol levels in the plasma,
promoting xanthoma regression, improving the cardiovas-
cular and hematological signs [79,83].
Dyslipidemias
Familial hypercholesterolemia (FH; OMIM#143890) is
an autosomal-dominant disease caused by a deficiency
in low-density lipoprotein (LDL) receptor (ADH1) activ-
ity or in LDL-related genes (ApoB and PCSK9), which
leads to obviously elevated LDL cholesterol (LDL-C) andcumulation of xanthoma cells (fine arrows) and dispersed lipid crystal
Nie et al. Orphanet Journal of Rare Diseases 2014, 9:179 Page 7 of 11
http://www.ojrd.com/content/9/1/179triglyceride concentrations [10,84]. The prevalence of
FH is estimated to be 1/300-500 (heterozygous type)
worldwide [84,85]. The underlying pathogenesis of FH is
the decreased clearance of apolipoprotein B-containing
lipoproteins and their subsequent accumulation in mul-
tiple tissues [22]. The diagnostic criteria for FH in adults
(>15 years of age) include hyper-LDL cholesterolemia
(untreated LDL-C level ≥180 mg/dL), tendonous xantho-
mas (xanthoma on the backs of the hands, elbows,
knees, etc.) or xanthoma tuberosum, and a family history
of FH or premature coronary artery disease [84]. Familial
dysbetalipoproteinemia may present with palmar crease
xanthomas, but familial hypercholesterolemia presents
with intertriginous xanthomas in children, and sitostero-
lemia and CTX present with tendonous xanthomas in
adults [86]. Lifestyle modification and high-potency sta-
tins should be the first-line treatment and can delay the
onset of coronary artery disease [84,87].
Neurologic symptoms and diarrhea, which are import-
ant features of CTX, are non-existent in patients with
sitosterolemia or FH [22]. Note also that the morphology
of xanthomatosis is variable. Depending on the clinical
morphology, localization, development, and progression
of this lipid storage disorder, xanthomas can present as
either eruptive, tuberous, tendonous, or planar [10,86].
CTX can be distinguished from other lipid storage disor-
ders by its specific clinical features such as childhood-
onset cataracts, progressive neurologic symptoms, mild
pulmonary insufficiency, increased plasma cholestanol
levels, and the results of the SSEP assessment [10,22].
Other inborn errors of bile acid metabolism
Other disorders of bile acid synthesis and metabolism in-
clude cholesterol 7α-hydroxylase deficiency (mutation in
the CYP7A1 gene), 3β-hydroxy-C27-steroid oxidoreductase
deficiency,and 2-methylacyl-CoA racemase deficiency [88].
Patients with cholesterol 7α-hydroxylase deficiency have
elevated serum cholesterol concentrations and are unre-
sponsive to hydroxymethylglutaryl (HMG)-CoA reductase
inhibitor therapy. Neonates with 3-β-hydroxy-C27-steroid
oxidoreductase deficiency show hepatomegaly, mild stea-
torrhea, elevated serum ALT and AST, hyperbilirubinemia,
and normal serum γ-glutamyl transpeptidase [89]. Defects
in 2-methylacyl-CoA racemase have profound effects on
both the bile acid and the fatty acid pathways. Patients may
present with a sensorimotor neuropathy in adults and with
a fat-soluble vitamin deficiency, hematochezia, and chole-
static liver disease in infants [90]. Bile acid therapy with
cholic acid (10 to 15 mg · kg−1 · day−1) has also been proved
effective in treating the above three metabolic disorders.
Diagnosis
Early detection and diagnosis of CTX is crucial because
early and long-term treatment of CTX with CDCAimproves neurological symptoms and even reverses the
progression of the disease [5,23,38,53,77]. However, an
obvious delay between symptom onset and diagnosis is
prevalent [5,38].
The diagnosis of CTX is mainly based on clinical find-
ings, biochemical testing, neuroimaging, and molecular
genetic analysis. A diagnosis of CTX should be considered
for patients with xanthomas and neurological symptoms
starting in childhood. It should be noted that the symptoms
might also start in adulthood [91]. The biochemical abnor-
malities of patients with CTX in the laboratory examination
include elevated plasma cholestanol level and increased
levels of bile alcohols in urine associated with a diminished
biliary concentration of chenodeoxycholic acid [22]. An
elevated plasma level of cholestanol is a feature of CTX
[10,22,43]. It was reported that the serum levels of 7-
α-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one
in patients with CTX were 100 times higher than normal
[92]. A new and sensitive multi-analyte blood test with
liquid chromatography–electrospray ionization-tandem
mass spectrometry (LC-ESI-MS/MS) methodology can
be used to quantify plasma ketostetrol bile acid precursors
such as 7-α-hydroxy-4-cholesten-3-one and 5-α-cholestanol
[43]. With the development of genetic analysis, MRI
and other neuroimaging technologies are not crucial for
the diagnosis of CTX, but could provide complementary
clinical information [93].
On the basis of a pool analysis of a screened inter-
national CTX series, Mignarri et al. developed an effect-
ive suspicion index for early diagnosis composed of
weighted scores related to indicators such as family his-
tory and systemic and neurological characteristics [38].
The indicators were classified as very strong (score = 100),
strong (score = 50), or moderate (score = 25). Childhood-
onset cataracts, diarrhea, and neonatal cholestatic jaundice
in combination with neurological features and dentate
nucleus abnormalities in MRI were demonstrated to be
strong indicators. Tendon xanthomas were considered
very strong indicators. Plasma cholestanol examination
with a total score ≥100 is requisite, as is CYP27A1 gene
analysis with a total sore ≥200 or the existence of one very
strong or four strong indicators. Using this efficient diag-
nostic tool, the investigators achieved a diagnostic age in
their study of only 10.6 ± 9.8 years, which compares favor-
ably to the previous average age at diagnosis of 35 years
(p <0.01) [38].
Management and prognosis
The management of CTX includes replacement therapy,
surgery, and other symptomatic therapy. Our knowledge
of the pathogenesis of CTX suggests that replacement
therapy involving bile acid supplementation can restore
bile acid synthesis by reducing plasma cholestanol levels
and eliminating bile alcohols. Moreover, the benefits
Nie et al. Orphanet Journal of Rare Diseases 2014, 9:179 Page 8 of 11
http://www.ojrd.com/content/9/1/179could be enhanced by administration of HMG-CoA re-
ductase inhibitors [22,94]. The potential mechanism of
bile acid therapy may be exogenous inhibition of bile
acid production by activating the bile acid negative
feedback mechanism. This would inhibit production of
the intermediate 7-α-hydroxy-4-cholesten-3-one, thereby
normalizing cholestanol concentration and preventing
the accumulation of cholestanol in tissues.
Replacement therapy involves administration of bile acids
such as CDCA, ursodeoxycholic acid (UDCA), cholic acid,
or taurocholic acid [95-97]. Compared to administration
of UDCA or taurocholic acid, CDCA treatment (750 mg/d)
is the therapy of choice for treating the neurological and
non-neurological symptoms of CTX, but cholic acid is also
efficient for non-neurological symptoms [39,41,44,73,96].
Bile acid therapy with cholic acid has also proven its
effectiveness in treating other lipid metabolic disorders
[88]. Administration of CDCA (750 mg/d) or cholic acid
can normalize plasma cholestanol and improve non-
neurological symptoms in many individual CTX cases, but
only CDCA can improve the neurological symptoms in pa-
tients with CTX [5,23,95,97]. Long-term replacement ther-
apy with CDCA can increase bone mineral content and
improve intestinal absorption of vitamin D by activating
the bile acid negative feedback mechanism [32]. Combin-
ation therapy with CDCA (300 mg/d) and pravastatin
(10 mg/d) can improve lipoprotein metabolism, inhibit
cholesterol synthesis, and reduce plasma levels of cholesta-
nol and plant sterols [98]. The efficacy of treatment with
HMG-CoA reductase inhibitors alone is controversial, and
some adverse effects such as hepatic dysfunction and
rhabdomyolysis may be observed [98,99]. Other possible
treatments that lack reliable clinical validation include vita-
min E supplementation, low-density lipoprotein apheresis,
and liver transplantation [5,21,24,100]. Surgical excision of
bilateral tendon may worsen the gait imbalance and cannot
prevent the deterioration of neurologically affected patients
[22]. Due to the diverse manifestations and signs of CTX,
symptomatic therapy is essential: antidepressant medication
in case of depression [24], antiepileptic therapy in case of
convulsive seizures [19], levodopa in case of parkinsonism,
and botulinum toxin in case of dystonia [61,101,102].
Beginning treatment with bile acid therapy as early as
possible is crucial for preventing neurological damage and
deterioration in patients with CTX [5,21,23,32,95,103]. In
a large series of 25 patients with CTX, 60% of patients
continued to deteriorate and 20% died in spite of the long-
term administration of CDCA, but survival was related
to age at diagnosis [5]. Ginanneschi et al. revealed that
CDCA treatment improved nerve conduction velocity
and promoted myelin synthesis in nerve fibers with re-
sidual unaffected axons in a series of 35 patients with
polyneuropathy, and the therapeutic effect depended
largely on the extent of irreversible structural damage[39]. Neurophysiological follow-up research might be rec-
ommended when patients with CTX present clinical
symptoms of peripheral neuropathy [45].
Discussion and unresolved questions
Monitoring plasma cholestanol levels can be used to as-
sess the biochemical effects of CDCA and cholic acid in
patients with CTX before and after treatment. However,
serum cholestanol level has no correlation with clinical
features [44]. A possible explanation is that increased
cholestanol level is not the only factor important for
pathogenesis in CTX. Further studies are required to
understand any other underlying mechanisms and to
provide reasonable explanations. Cerebral WM lesions
and cerebellar vacuolation have been described in a pa-
tient with CTX with progressive ataxia [49,75]. White
matter changes in patients with CTX suggest the coex-
istence of demyelinating and axonopathic lesions in
CTX [45]. Moreover, further studies are needed to dis-
cover why some patients with CTX develop WM lesions
in the brain.
Many clinical studies of CTX have been published, but
basic animal research on the pathogenesis of CTX is still
not commonly reported. The CYP27A1 gene knockout
mice do not present with xanthomas in brain or tendon.
However, mice may be able to compensate for the loss
of the alternative bile acid synthesis pathway [8,104].
Transgenic mice overexpressing the CYP27A1 gene do
not show increased synthesis of bile acid [8]. The reason
for the obvious difference between the animal models
and humans with CTX is not known with certainty. The
relationship between the deposition of cholestanol and
the development of xanthomas deserves further study.
Conclusion
CTX is an inherited lipid metabolic disorder with diverse
manifestations. The classical symptoms and signs, namely
elevated levels of cholestanol and bile alcohols in serum
and urine, cranial magnetic resonance imaging, and muta-
tion in the CYP27A1 gene, confirm the diagnosis. Patients
with CTX have an average diagnosed age of 35 years and a
diagnostic delay of 16 years. Early diagnosis and long-term
treatment with CDCA (750 mg/d) can improve neuro-
logical symptoms and contribute to a better prognosis.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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